• Investors
  • News
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
  • Inhalers
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • ICOone Nasal
    • Patents
  • Development capabilities
    • Our inhalers
    • Formulation
    • Pharmaceutical Analysis
  • Pipeline
  • Partner with us
  • Investors
  • Search
  • Menu Menu

    Iconovo to Nasdaq first North

    April 10, 2018/in News /by Eva Norell

    Nasdaq welcomes Iconovo to First North.

    Share this entry
    • Share on Twitter
    • Share on LinkedIn
    • Share by Mail
    https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png 0 0 Eva Norell https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png Eva Norell2018-04-10 13:03:152018-04-10 13:03:15Iconovo to Nasdaq first North

    Possessing a unique combination

    of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

    ICONOVO AB

    VISITING ADDRESS
    Ideon, Delta 6 Lund
    Ideongatan 3B

    POSTAL ADDRESS
    Iconovo AB
    Ideongatan 3A-B
    SE-223 62 LUND
    Sweden

    CONTACT

    Phone: +46 46 275 67 77

    Director Business Development and Alliances
    Måns Österberg
    Mail: mans.osterberg@iconovo.se

    Interim CEO
    Anders Månsson
    Mail: anders.mansson@iconovo.se

    Press releases

    Subscribe

    Follow us on Linkedin

    Erbjudandet i Iconovo övertecknat inför börsnotering på First North (only... NOTICE OF ANNUAL GENERAL MEETING IN ICONOVO AB
    Scroll to top